P28482 (MK01_HUMAN) Homo sapiens (Human)

Mitogen-activated protein kinase 1 UniProtKBInterProSTRINGInteractive Modelling

360 aa; Sequence (Fasta) ; (Isoform 2); 23 identical sequences

Available Structures

112 Experimental Structures

DescriptionOligo-stateLigandsStructureRange
Heterodimeric structure of ERK2 and RSK1 Heteromer
Q15418;
ANP;SO4;NA;9-360
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide Heteromer
P36507;
ANP;9-360
Assess
Phospho-ERK2 bound to bivalent inhibitor SBP3 Heteromer
Q15418;
GOL;FRZ;AKS;10-360
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide Heteromer
Q9BUB5;
ANP;9-358
Assess
Structure of Non-Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain Heteromer
Q9Z297;
NA;11-360
Assess
Phospho-ERK2 bound to bivalent inhibitor SBP2 Heteromer
Q15418;
GOL;FRZ;90A;10-359
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide Heteromer
Q15418;
ANP;11-359
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide Heteromer
Q15418;
ANP;10-358
Assess
Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors. Heteromer
P40763;
5ID;10-358
Assess
Structure of Dually Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain Heteromer
Q15121;
11-358
Assess
Structure of the complex between ERK2 phosphomimetic mutant and PEA-15 Heteromer
Q15121;
ADP;SO4;11-357
Assess
Crystal structure of HePTP in complex with a dually phosphorylated Erk2 peptide mimetic Heteromer
P35236;
CL;GOL;185-188
Assess
Crystal structure of HePTP in complex with a monophosphorylated Erk2 peptide Heteromer
P35236;
TAR;GOL;185-188
Assess
Complex of ERK2 with norathyriolmonomerNRA;SO4;4-360
Assess
Complex of ERK2 with caffeic acidmonomerDHC;SO4;PEG;DMS;6-357
Assess
Complex of ERK2 with catecholmonomerCAQ;SO4;NH4;7-357
Assess
Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydr…monomerSO4;E86;8-358
Assess
ERK2 mini-fragment bindingmonomerSO4;PZO;8-357
Assess
Crystal Structure of ERK2 in complex with compound 22monomer6QB;EDO;9-358
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ER8;8-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;EQW;8-357
Assess
Erk2 signalling proteinmonomerSO4;F0H;8-357
Assess
ERK2 mini-fragment bindingmonomerSO4;2AI;8-357
Assess
ERK2 complexed with a N-H tetrahydroazaindazolemonomer4VB;9-358
Assess
Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinasemonomer4VF;SO4;9-358
Assess
Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinasemonomer4VJ;SO4;9-358
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ESQ;8-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ERK;8-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ERZ;8-357
Assess
Crystal Structure of the ERK2 complexed with E63monomerE63;SO4;EDO;8-357
Assess
Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinasemonomer4VG;SO4;9-358
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptidemonomerANP;9-358
Assess
Crystal Structure of the ERK2 complexed with E71monomerE71;SO4;EDO;8-357
Assess
Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrim…monomerSO4;Z48;8-357
Assess
Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivativemonomerF29;8-357
Assess
The structure of ERK2 in complex with a small molecule inhibitormonomerFRZ;8-357
Assess
Structure of human ERK2 in complex with SCH772984 revealing a novel inhibitor-induced binding pocketmonomerEDO;SO4;38Z;10-358
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;DMS;F3Z;8-356
Assess
Phospho-ERK2 bound to AMP-PCPmonomerACP;GOL;MG;10-358
Assess
Crystal Structure of ERKs in complex with 5-chlorobenzo[d]oxazol-2-aminemonomer36R;IMD;12-360
Assess
Crystal Structure of the ERK2 complexed with EK9monomerEK9;SO4;EDO;9-357
Assess
Crystal Structure of the ERK2 complexed with EK7monomerEK7;SO4;GOL;9-357
Assess
Crystal Structure of the ERK2 complexed with E57monomerE57;SO4;EDO;9-357
Assess
Crystal structure of ERK2 in complex with an inhibitor 14Kmonomer41B;12-360
Assess
Crystal Structure of ERK2 in complex with (S)-2-((9H-purin-6-yl)amino)-3-phenylpropan-1-olmonomer36Q;12-360
Assess
Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-aminemonomerEMU;IMD;12-360
Assess
phosphorylated ERK2 with AMP-PNPmonomerANP;MG;10-358
Assess
Crystal Structure of ERK2 in complex with 5H-pyrrolo[2,3-b]pyrazinemonomer36N;IMD;12-360
Assess
Structure of ERK2 in complex with VTX-11e, 4-{2-[(2-CHLORO-4-FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-…monomer22×EDO;SO4;CL;390;11-358
Assess
Erk2 signalling proteinmonomerSO4;DMS;GOL;F0E;10-357
Assess
ERK2 mini-fragment bindingmonomerSO4;HVK;11-358
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;DMS;EVK;10-357
Assess
Crystal Structure of the ERK2 complexed with E94monomerE94;SO4;EDO;GOL;11-358
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8XH;11-358
Assess
Crystal Structure of the ERK2monomerEK0;SO4;11-358
Assess
Crystal Structure of the ERK2 complexed with EK2monomerEK2;SO4;EDO;11-358
Assess
Crystal Structure of the ERK2 complexed with EK3monomerEK3;EDO;GOL;11-358
Assess
ERK2 complexed with 2-pyridiyl tetrahydroazaindazolemonomerNI;4V9;11-358
Assess
ERK2 complexed with N-benzylpyridone tetrahydroazaindazolemonomer4V8;NI;11-358
Assess
phosphorylated ERK2 with GDC-0994monomer6QB;11-358
Assess
ERK2 mini-fragment bindingmonomerSO4;HV2;11-357
Assess
ERK2 mini-fragment bindingmonomerSO4;HVQ;11-357
Assess
ERK2 mini-fragment bindingmonomerSO4;HVB;11-357
Assess
ERK2 mini-fragment bindingmonomerSO4;HRZ;11-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;EU2;11-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ERW;11-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ESN;11-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;EQT;11-357
Assess
In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitormonomer6TS;SO4;11-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;DMS;EVQ;11-357
Assess
ERK2 mini-fragment bindingmonomerSO4;HVE;11-357
Assess
A Clickable Covalent ERK 1/2 InhibitormonomerSO4;6TT;11-357
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;EQZ;11-357
Assess
WT ERK2 with compound 2507-8monomerSO4;GOL;KJ7;KJ4;10-356
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ESK;11-357
Assess
Crystal Structure of the ERK2 complexed with EK5monomerEK5;SO4;GOL;EDO;11-357
Assess
Crystal structure of ERK2 covalently bound to SM1-71monomerSO4;6H3; 13×EDO;CL;10-356
Assess
ERK2 mini-fragment bindingmonomerSO4;HUH;11-357
Assess
Crystal Structure of the ERK2 complexed with EK6monomerEK6;SO4;EDO;11-357
Assess
Crystal Structure of the ERK2 complexed with E75monomerE75;SO4;EDO;11-357
Assess
A multiconformer ligand model of EK6 bound to ERK2monomerSO4;EDO;EK6;11-357
Assess
Crystal Structure of the ERK2monomerE28;SO4;EDO;11-357
Assess
phosphorylated ERK2 with SCH-CPD336monomerN0V;10-356
Assess
The structure of ERK2 in complex with FR148083monomer1FM;11-357
Assess
ERK2 mini-fragment bindingmonomerSO4;HOW;11-356
Assess
ERK2 mini-fragment bindingmonomerSO4;IPH;11-356
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…monomerSO4;ESW;11-356
Assess
Crystal Structure of the ERK2 complexed with EK4monomerEK4;GOL;SO4;EDO;11-356
Assess
Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-7-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyr…monomer362;12-357
Assess
Crystal Structure of ERK2 in complex with 7-(1-benzyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[…monomer35W;12-357
Assess
Human ERK2 in complex with an inhibitormonomerSO4;CQ8;11-355
Assess
Human ERK2 in complex with an irreversible inhibitormonomerSO4;CQ3;11-355
Assess
Human ERK2 in complex with an irreversible inhibitormonomerSO4;CQ6;11-355
Assess
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Inhibitors of Erk2monomer2SH;13-357
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8XK;11-355
Assess
STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MA…monomerSO4;SB2;16-360
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8QB;11-355
Assess
Crystal Structure of ERK2 in complex with 7-(1-propyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[…monomer35X;13-357
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8XB;11-355
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8XE;11-355
Assess
Crystal Structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-aminemonomer36O;13-357
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8XN;11-355
Assess
Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazinemonomer363;13-357
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8X2;11-355
Assess
Crystal structure of ERK2 G169D mutantmonomer13-357
Assess
Human Erk2 with an Erk1/2 inhibitormonomerSO4;8X5;12-355
Assess
Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(…monomerSO4;82A;15-358
Assess
Crystal structure of ERK2 in complex with N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrol…monomerSO4;33A;15-358
Assess
Complex of ERK2 with 5,7-dihydroxychromonemonomerB7S;SO4;BEZ;15-357
Assess
HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364.monomerLHZ;SO4;EDO;18-356
Assess
Inhibitor of ERK2monomerSO4;KE8;19-357
Assess
Crystal structure of ERK2 in complex with N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-ca…monomerSO4;19A;19-357
Assess

1 Homology model

Oligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
monomer38Z;0.894qtb.1.A12-357
87.90
Assess

1 Homology model built on isoform sequence

IsoformOligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
Isoform 2monomer36Q;0.824qp3.1.A12-316
99.05
Assess

Alignments